Sovereign capability, onshore, with a world leading R&D incentive.
Human grade DNA and RNA manufacturing is concentrated in a few countries. Syngenis brings that capability onshore.
Sovereign manufacturing, on home soil.
Syngenis operates Australia's only commercial RNA manufacturing facility, at Bentley, Western Australia. Performing discovery and manufacture in one place, in Australia, keeps valuable intellectual property at home and removes the delay, cost and complexity of importing material and coordinating unrelated suppliers across borders. For a country that has relied heavily on offshore suppliers for advanced nucleic acid manufacturing, this is a genuine strategic capability.
The R&D Tax Incentive advantage.
Because all Syngenis work is performed on Australian soil, it changes the compliance position of Australian entities that currently send DNA and RNA work overseas. For companies with aggregated turnover under 20 million dollars, the Research and Development Tax Incentive returns up to 43.5 cents in every eligible dollar as a refundable cash offset.
- No Advance Overseas Finding required, because the work is performed in Australia.
- The Australian first rule has teeth. An Overseas Finding is only granted where it was not reasonable to source the capability in Australia; with a local option, that bar is harder to clear.
- Full compliance support, including project records, batch records and contemporaneous documentation to support a claim and any review.
Why it matters.
- Protect intellectual property by keeping it in one place, in Australia.
- Reduce lead times compared with offshore suppliers.
- Support Australian research funding and sovereign capability.
General information, not tax advice.
This page describes general considerations, not tax advice. We recommend that clients confirm their own position with their tax adviser before relying on any R&D Tax Incentive treatment.
R&DTI figures are current for the 2025-26 and 2026-27 income years.
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.